---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-017806"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-25T00:01:19.267397+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioventus amends CartiHeal acquisition, defers $215M upfront, lowers sales milestone to $75M

## Summary
- Deferred $215M of $315M upfront; paid in five tranches 2023–2027 with 8% annual interest.
- Contingent ~$135M now triggered at $75M trailing sales (down from $100M).
- Expected close by end of July 2022; upfront ~$100M (incl. $50M escrowed).
- Bioventus to pay ~$8M of CartiHeal's transaction fees.
- Additional milestones: First Paper $50M, Additional Publication $25M, etc., with interest.

## SEC filing metadata
- accession: 0001628280-22-017806
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022017806/0001628280-22-017806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022017806/bvs-20220617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-017806
- JSON: https://secwatch.observer/filing/0001628280-22-017806.json
- Plain text: https://secwatch.observer/filing/0001628280-22-017806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.